1. Home
  2. NEXT vs TSHA Comparison

NEXT vs TSHA Comparison

Compare NEXT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$5.02

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.32

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
TSHA
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NEXT
TSHA
Price
$5.02
$5.32
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
$9.00
$10.56
AVG Volume (30 Days)
3.6M
3.4M
Earning Date
02-27-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,310,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.99
$1.05
52 Week High
$12.12
$6.02

Technical Indicators

Market Signals
Indicator
NEXT
TSHA
Relative Strength Index (RSI) 34.71 50.81
Support Level $5.23 $4.80
Resistance Level $5.47 $6.02
Average True Range (ATR) 0.21 0.33
MACD -0.01 -0.10
Stochastic Oscillator 29.01 43.03

Price Performance

Historical Comparison
NEXT
TSHA

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: